Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN®) Implant in Patients with Refractory Diabetic Macular Edema

Abstract Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME). Methods: Retrospective study on 44 eyes with chronic DME that received intravitr...

Full description

Saved in:
Bibliographic Details
Published inOphthalmic research Vol. 67; no. 1; pp. 600 - 610
Main Authors Darwisch, Warda, della Volpe-Waizel, Maria, Roberts, Philipp K., Boden, Karl T., Szurman, Peter, Rickmann, Annekatrin
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 01.01.2024
Subjects
Aged
Corticosteroids
Diabetic Retinopathy - complications
Diabetic Retinopathy - diagnosis
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - physiopathology
Diabetics
Dropsy
Drug Implants
Edema
Female
Fluocinolone
Fluocinolone acetonide
Fluocinolone Acetonide - administration & dosage
Follow-Up Studies
Glucocorticoids - administration & dosage
Humans
Intraocular Pressure - drug effects
Intraocular Pressure - physiology
Intravitreal Injections
Macular Edema - diagnosis
Macular Edema - drug therapy
Macular Edema - etiology
Male
Middle Aged
Patient compliance
Research Article
Retrospective Studies
Tomography, Optical Coherence - methods
Treatment Outcome
Triamcinolone
Vascular endothelial growth factor
Visual Acuity
South Dakota
Virginia
Germany
0.19 mg fluocinolone acetonide
IVOM
ILUVIEN
Diabetic macular edema
Online AccessGet full text
ISSN0030-3747
1423-0259
1423-0259
DOI10.1159/000540459

Cover

Abstract Abstract Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME). Methods: Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments. Results: The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3). Conclusion: Even though patients’ visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.
AbstractList Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME). Methods: Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments. Results: The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3). Conclusion: Even though patients’ visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.
Abstract Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME). Methods: Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments. Results: The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3). Conclusion: Even though patients’ visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.
The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME).INTRODUCTIONThe aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME).Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments.METHODSRetrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments.The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3).RESULTSThe FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3).Even though patients' visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.CONCLUSIONEven though patients' visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.
Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME). Methods: Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments. Results: The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3). Conclusion: Even though patients' visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME. Keywords: Diabetic macular edema, 0.19 mg fluocinolone acetonide, ILUVIEN, IVOM
The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with refractory diabetic macular edema (DME). Retrospective study on 44 eyes with chronic DME that received intravitreal FAc implant and were previously treated with intravitreal dexamethasone, triamcinolone, or anti-vascular endothelial growth factor. We assessed best-corrected visual acuity (BCVA), central maximum thickness (CMT), and foveal thickness (FT) as measured by spectral-domain optical coherence tomography (Spectralis OCT; Heidelberg Engineering). Secondary outcomes were intraocular pressure (IOP), adverse events, time to additional treatments. The FAc implant significantly reduced the CMT (baseline 541.23 ± 155.29 µm, p < 0.001) and FT (baseline 460.34 ± 139.28 µm, p < 0.001) for up to 36 months. Despite postoperative visual improvement over time, BCVA did not significantly shift from baseline (0.55 ± 0.38 logMAR, p = 0.568). The FAc implant effect diminished after 21.34 ± 12.74 months. IOP increased in 9% of eyes (n = 4) but was well controlled under topical (n = 1) or surgical therapy (n = 3). Even though patients' visual recovery does not benefit significantly, the FAc implant addresses the important pillars of chronic DME therapy regarding reduced injection frequency and reduced DME.
Audience Academic
Author della Volpe-Waizel, Maria
Szurman, Peter
Boden, Karl T.
Roberts, Philipp K.
Rickmann, Annekatrin
Darwisch, Warda
Author_xml – sequence: 1
  givenname: Warda
  surname: Darwisch
  fullname: Darwisch, Warda
– sequence: 2
  givenname: Maria
  surname: della Volpe-Waizel
  fullname: della Volpe-Waizel, Maria
– sequence: 3
  givenname: Philipp K.
  surname: Roberts
  fullname: Roberts, Philipp K.
– sequence: 4
  givenname: Karl T.
  surname: Boden
  fullname: Boden, Karl T.
– sequence: 5
  givenname: Peter
  surname: Szurman
  fullname: Szurman, Peter
– sequence: 6
  givenname: Annekatrin
  surname: Rickmann
  fullname: Rickmann, Annekatrin
  email: *Annekatrin Rickmann, annekatrin.rickmann@kksaar.de
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39159620$$D View this record in MEDLINE/PubMed
BookMark eNptksFu1DAQhi1URLeFA3eELPXSHlImdtLEx1XZwkoLRQvlGnnt8daQ2IvtCPVdeAYegifDVcpKSJUPtmY-z_97PEfkwHmHhLws4bwsa_EGAOoKqlo8IbOyYrwAVosDMgPgUPCmag7JUYzfADIs4Bk55CKfLhjMyK81yr5YWYN0jXHsU6TSJAw03SKd68E6G1OQyXpHvaGSfrZu2yPNyoIOW3rVj15Z5_vsiM4VJu-sRnq6XN18XS4-_vl9RpfDrpcuUevop1wIXdb4adNtFjRBquTDHX1r5QaTVfSDVGMvA11oHORz8tTIPuKLh_2Y3Fwtvly-L1bX75aX81WhuLhIRQWghdoYLVFjzYSpNENV6twbYC03TSuMbhulFAMpBK-Y0shl07JGCS4rfkxOp7q74H-MGFM32Kiwz7bRj7HjIKqWlW3DMnoyoVvZY2ed8bk76h7v5i2DmjPBeKbOH6Hyyq-yKrfK2Bz_78LrBwfjZkDd7YIdZLjr_n1UBs4mQAUfY0CzR0ro7oeg2w9BZl9N7HcZthj25D598mj6er2YiG6nDf8Lqei3BA
Cites_doi 10.2147/OPTH.S206769
10.3928/23258160-20230215-01
10.1159/000458539
10.3390/ijms19040942
10.1016/j.ophtha.2010.08.016
10.26355/eurrev_202303_31536
10.1080/03007995.2018.1560779
10.3390/pharmaceutics13010072
10.1016/j.ophtha.2012.09.014
10.1016/j.ophtha.2012.04.030
10.1007/s40123-022-00455-5
10.1097/IAE.0000000000003827
10.1159/000520411
10.1155/2018/8289253
10.1016/j.ajo.2016.09.012
10.1007/s40123-018-0155-5
10.1016/j.ophtha.2013.06.033
10.1097/IAE.0000000000000726
10.1080/03007995.2017.1366662
10.1038/s41433-021-01921-3
10.2337/diacare.26.9.2653
10.3109/08820539909069541
10.1038/s41433-021-01542-w
10.1001/jamaophthalmol.2017.6565
10.1016/j.exer.2016.08.005
10.1159/000515306
10.1016/j.ophtha.2010.02.031
10.1016/S0140-6736(15)00057-4
10.1136/bjophthalmol-2020-315984
10.1167/iovs.04-0905
10.1007/s00417-022-05564-2
10.1089/jop.2014.0100
10.1177/1120672120901691
10.3928/23258160-20200501-09
10.31487/j.scr.2020.09.05
10.1016/j.ajo.2022.09.017
10.1016/j.ophtha.2010.03.045
10.3390/pharmaceutics14040723
10.1016/j.ophtha.2022.01.015
10.1136/bmjophth-2019-000416
10.1517/17425247.5.9.1039
10.1016/j.ophtha.2015.03.024
ContentType Journal Article
Copyright 2024 The Author(s). Published by S. Karger AG, Basel
2024 The Author(s). Published by S. Karger AG, Basel.
COPYRIGHT 2024 S. Karger AG
Copyright_xml – notice: 2024 The Author(s). Published by S. Karger AG, Basel
– notice: 2024 The Author(s). Published by S. Karger AG, Basel.
– notice: COPYRIGHT 2024 S. Karger AG
DBID M--
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1159/000540459
DatabaseName Karger Open Journals (Free, activated by CARLI)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: M--
  name: Karger Open Journals (Free, activated by CARLI)
  url: https://www.karger.com/OpenAccess
  sourceTypes:
    Enrichment Source
    Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1423-0259
EndPage 610
ExternalDocumentID A820532923
39159620
10_1159_000540459
540459
Genre Journal Article
GeographicLocations South Dakota
Virginia
Germany
GeographicLocations_xml – name: South Dakota
– name: Germany
– name: Virginia
GroupedDBID ---
0~B
123
3O.
4.4
5RE
AAYIC
ABBTS
ABPAZ
ABWCG
ACGFS
ACNCT
ACPRK
ACPSR
ADBBV
AENEX
AEYAO
AFRAH
AHFRZ
AHMBA
ALDHI
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AZPMC
CS3
DU5
E0A
EBS
EMOBN
F5P
FB.
GROUPED_DOAJ
HZ~
IAO
IY7
KUZGX
M--
N9A
O1H
O9-
OK1
RKO
UJ6
WH7
AAYXX
CITATION
.GJ
0~5
29N
30W
329
34G
39C
3O-
53G
7X7
88E
8AO
8FI
8FJ
8FW
8UI
AALGM
ABJNI
ABUWG
ACQXL
ADAGL
AFJJK
AFKRA
AFSIO
BENPR
BPHCQ
BVXVI
CAG
CCPQU
CGR
COF
CUY
CVF
CYUIP
ECM
EIF
EJD
FYUFA
HMCUK
IHR
INH
ITC
M1P
NPM
PHGZT
PQQKQ
PROAC
PSQYO
RIG
RXVBD
UKHRP
ZGI
ZXP
7X8
ID FETCH-LOGICAL-c396t-400d9cbfdaede529f4d2ec1d1150283f789fd87ccc20a99342cde3a7827c93a43
IEDL.DBID M--
ISSN 0030-3747
1423-0259
IngestDate Sun Sep 28 12:02:39 EDT 2025
Thu Apr 17 06:55:24 EDT 2025
Tue Apr 15 04:05:05 EDT 2025
Thu Apr 03 06:55:11 EDT 2025
Tue Aug 05 12:06:28 EDT 2025
Fri Apr 25 05:07:32 EDT 2025
Fri Apr 25 05:07:44 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords 0.19 mg fluocinolone acetonide
IVOM
ILUVIEN
Diabetic macular edema
Language English
License This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
https://creativecommons.org/licenses/by-nc/4.0
2024 The Author(s). Published by S. Karger AG, Basel.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c396t-400d9cbfdaede529f4d2ec1d1150283f789fd87ccc20a99342cde3a7827c93a43
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://karger.com/doi/10.1159/000540459
PMID 39159620
PQID 3094821872
PQPubID 23479
PageCount 11
ParticipantIDs pubmed_primary_39159620
gale_infotracacademiconefile_A820532923
proquest_miscellaneous_3094821872
crossref_primary_10_1159_000540459
karger_primary_540459
gale_infotracmisc_A820532923
PublicationCentury 2000
PublicationDate 2024-01-01
PublicationDateYYYYMMDD 2024-01-01
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-01
  day: 01
PublicationDecade 2020
PublicationPlace Basel, Switzerland
PublicationPlace_xml – name: Basel, Switzerland
– name: Switzerland
PublicationTitle Ophthalmic research
PublicationTitleAlternate Ophthalmic Res
PublicationYear 2024
Publisher S. Karger AG
Publisher_xml – name: S. Karger AG
References Khurana RN, Appa SN, McCannel CA, Elman MJ, Wittenberg SE, Parks DJ, . Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology. 2014;121(1):67–71.
Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, . Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
Deuchler SK, Schubert R, Singh P, Chedid A, Kenikstul N, Scott J, . Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2537–47.
Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, . Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.
Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study. Ophthalmology. 2022;129(6):605–13.
Avogaro F, Florido A, Calandri A, Toja F, Vingolo EM. Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data. Eur Rev Med Pharmacol Sci. 2023;27(5):1759–66.
Gonzalez VH, Luo C, Almeida DRP, Cutino A, Coughlin B, Kasper J, . Better baseline vision leads to better outcomes after the 0.19-mg fluocinolone acetonide intravitreal implant in diabetic macular edema. Retina. 2023;43(8):1301–7.
Riemann CD, Eaton AM, Cutino A. Reduction in retinal thickness fluctuations after treatment with fluocinolone acetonide implant for DME: a post-hoc analysis of the USER study. Ophthalmic Surg Lasers Imaging Retina. 2020;51(5):298–306.
van Nunen LX, Zimmermann FM, Tonino PAL, Barbato E, Baumbach A, Engstrøm T, . Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet. 2015;386(10006):1853–60.
Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv. 2008;5(9):1039–46.
Brambati M, Borrelli E, Capone L, Querques L, Sacconi R, Battista M, . Changes in macular perfusion after ILUVIEN® intravitreal implant for diabetic macular edema: an OCTA study. Ophthalmol Ther. 2022;11(2):653–60.
Byun M, Osher J, Riemann CD. Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema. BMJ Open Ophthalmol. 2020;5(1):e000416.
Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. BioMed Res Int. 2018;2018:8289253.
Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, . Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–4.
Adams OE, Schechet SA, Hariprasad SM. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency. Eur J Ophthalmol. 2021;31(2):612–9.
Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, . Efficacy and safety of intravitreal fluocinolone acetonide implant for chronic diabetic macular edema previously treated in real-life practice: the REALFAc study. Pharmaceutics. 2022;14(4):723.
Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, . Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–69.
Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, . Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7.
Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina. 2015;35(12):2440–9.
Kodjikian L, Baillif S, Creuzot-Garcher C, Delyfer M-N, Matonti F, Weber M, . Real-World efficacy and safety of fluocinolone acetonide implant for diabetic macular edema: a systematic review. Pharmaceutics. 2021;13(1):72.
Adsuara CM, Adsuara CM, Mata-Moret L, Castro-Navarro V, Montero-Hernández J. Management of anterior chamber dislocation of a fluocinolone acetonide implant: a case report. SCR. 2020:1–4.
Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–64.
Merrill PT, Holekamp N, Roth D, Kasper J, Grigorian R; PALADIN Study Group. The 0.19-mg fluocinolone acetonide intravitreal implant reduces treatment burden in diabetic macular edema. Am J Ophthalmol. 2023;248:16–23.
Holden SE, Kapik B, Beiderbeck AB, Currie CJ. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Curr Med Res Opin. 2019;35(7):1165–76.
Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, . Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–51.
Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, . Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2021;105(3):414–9.
Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, . A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–86.e2.
Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33(Suppl 2):33–43.
Kolomeyer AM, Eichenbaum DA, Kiernan DF, Suñer IJ, Hariprasad SM. The 0.19-mg fluocinolone acetonide implant for the treatment of diabetic macular edema: an expert consensus. Ophthalmic Surg Lasers Imaging Retina. 2023;54(3):166–73.
Cicinelli MV, Rabiolo A, Capone L, Di Biase C, Lattanzio R, Bandello F. Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular oedema evaluated as the area-under-the-curve. Eye. 2023;37(2):242–8.
Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–94.
Urbančič M, Gardašević Topčić I. Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective. Clin Ophthalmol. 2019;13:829–40.
Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J; Medisoft Audit Group. Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye. 2022;36(5):1012–8.
Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, . Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77.e35.
Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):942.
Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, . Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72–9.
Stewart EA, Saker S, Amoaku WM. Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro. Exp Eye Res. 2016;151:75–81.
Pessoa B, Ferreira A, Leite J, Figueira J, Meireles A, Beirão JM. Optical coherence tomography biomarkers: vitreous status influence in outcomes for diabetic macular edema therapy with 0.19-mg fluocinolone acetonide implant. Ophthalmic Res. 2021;64(4):639–47.
Kane FE, Green KE. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. J Ocul Pharmacol Ther. 2015;31(1):11–6.
Eaton A, Koh SS, Jimenez J, Riemann CD. The USER study: a Chart review of patients receiving a 0.2 µg/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8(1):51–62.
Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14(4):223–32.
Pessoa B, Castro C, Ferreira A, Leite J, Heitor J, Menéres P, . Changes in ganglion cell layer thickness after treatment with the 0.2 µg/day fluocinolone acetonide implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema. Ophthalmic Res. 2022;65(3):310–20.
ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref39
ref16
ref38
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref42
ref41
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
ref40
References_xml – reference: Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, Do DV, . Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2010;117(11):2146–51.
– reference: van Nunen LX, Zimmermann FM, Tonino PAL, Barbato E, Baumbach A, Engstrøm T, . Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial. Lancet. 2015;386(10006):1853–60.
– reference: Kolomeyer AM, Eichenbaum DA, Kiernan DF, Suñer IJ, Hariprasad SM. The 0.19-mg fluocinolone acetonide implant for the treatment of diabetic macular edema: an expert consensus. Ophthalmic Surg Lasers Imaging Retina. 2023;54(3):166–73.
– reference: Kodjikian L, Bellocq D, Mathis T. Pharmacological management of diabetic macular edema in real-life observational studies. BioMed Res Int. 2018;2018:8289253.
– reference: Singer MA, Sheth V, Mansour SE, Coughlin B, Gonzalez VH. Three-year safety and efficacy of the 0.19-mg fluocinolone acetonide intravitreal implant for diabetic macular edema: the PALADIN study. Ophthalmology. 2022;129(6):605–13.
– reference: Avogaro F, Florido A, Calandri A, Toja F, Vingolo EM. Efficacy of 190 mcg fluocinolone acetonide intravitreal implant: microperimetry and OCT real-life data. Eur Rev Med Pharmacol Sci. 2023;27(5):1759–66.
– reference: Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–64.
– reference: Cicinelli MV, Rabiolo A, Capone L, Di Biase C, Lattanzio R, Bandello F. Factors associated with the response to fluocinolone acetonide 0.19 mg in diabetic macular oedema evaluated as the area-under-the-curve. Eye. 2023;37(2):242–8.
– reference: Adsuara CM, Adsuara CM, Mata-Moret L, Castro-Navarro V, Montero-Hernández J. Management of anterior chamber dislocation of a fluocinolone acetonide implant: a case report. SCR. 2020:1–4.
– reference: Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, . Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–69.
– reference: Byun M, Osher J, Riemann CD. Fluocinolone acetonide (0.19 mg) intravitreal implant reduces treatment burden and improves practice resource utilisation for patients with diabetic macular oedema. BMJ Open Ophthalmol. 2020;5(1):e000416.
– reference: Kane FE, Green KE. Ocular pharmacokinetics of fluocinolone acetonide following Iluvien implantation in the vitreous humor of rabbits. J Ocul Pharmacol Ther. 2015;31(1):11–6.
– reference: Riemann CD, Eaton AM, Cutino A. Reduction in retinal thickness fluctuations after treatment with fluocinolone acetonide implant for DME: a post-hoc analysis of the USER study. Ophthalmic Surg Lasers Imaging Retina. 2020;51(5):298–306.
– reference: Gonzalez VH, Luo C, Almeida DRP, Cutino A, Coughlin B, Kasper J, . Better baseline vision leads to better outcomes after the 0.19-mg fluocinolone acetonide intravitreal implant in diabetic macular edema. Retina. 2023;43(8):1301–7.
– reference: Eaton A, Koh SS, Jimenez J, Riemann CD. The USER study: a Chart review of patients receiving a 0.2 µg/day fluocinolone acetonide implant for diabetic macular edema. Ophthalmol Ther. 2019;8(1):51–62.
– reference: Das A, McGuire PG, Rangasamy S. Diabetic macular edema: pathophysiology and novel therapeutic targets. Ophthalmology. 2015;122(7):1375–94.
– reference: Urbančič M, Gardašević Topčić I. Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective. Clin Ophthalmol. 2019;13:829–40.
– reference: Adams OE, Schechet SA, Hariprasad SM. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency. Eur J Ophthalmol. 2021;31(2):612–9.
– reference: Deuchler SK, Schubert R, Singh P, Chedid A, Kenikstul N, Scott J, . Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study. Graefes Arch Clin Exp Ophthalmol. 2022;260(8):2537–47.
– reference: Michaelides M, Kaines A, Hamilton RD, Fraser-Bell S, Rajendram R, Quhill F, . A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078–86.e2.
– reference: Yang Y, Bailey C, Loewenstein A, Massin P. Intravitreal corticosteroids in diabetic macular edema: pharmacokinetic considerations. Retina. 2015;35(12):2440–9.
– reference: Campochiaro PA, Brown DM, Pearson A, Chen S, Boyer D, Ruiz-Moreno J, . Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology. 2012;119(10):2125–32.
– reference: Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J; Medisoft Audit Group. Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye. 2022;36(5):1012–8.
– reference: Antcliff RJ, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthalmol. 1999;14(4):223–32.
– reference: Currie CJ, Holden SE, Owens DR. Patterns of retinal thickness prior to and following treatment with fluocinolone acetonide 190 µg intravitreal implant for diabetic macular edema. Curr Med Res Opin. 2017;33(Suppl 2):33–43.
– reference: Diabetic Retinopathy Clinical Research Network; Elman MJ, Aiello LP, Beck RW, Bressler NM, Bressler SB, Edwards AR, . Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–77.e35.
– reference: Schmidt-Erfurth U, Garcia-Arumi J, Bandello F, Berg K, Chakravarthy U, Gerendas BS, . Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA). Ophthalmologica. 2017;237(4):185–222.
– reference: Stewart EA, Saker S, Amoaku WM. Dexamethasone reverses the effects of high glucose on human retinal endothelial cell permeability and proliferation in vitro. Exp Eye Res. 2016;151:75–81.
– reference: Kodjikian L, Baillif S, Creuzot-Garcher C, Delyfer M-N, Matonti F, Weber M, . Real-World efficacy and safety of fluocinolone acetonide implant for diabetic macular edema: a systematic review. Pharmaceutics. 2021;13(1):72.
– reference: Tamura H, Miyamoto K, Kiryu J, Miyahara S, Katsuta H, Hirose F, . Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci. 2005;46(4):1440–4.
– reference: Pessoa B, Ferreira A, Leite J, Figueira J, Meireles A, Beirão JM. Optical coherence tomography biomarkers: vitreous status influence in outcomes for diabetic macular edema therapy with 0.19-mg fluocinolone acetonide implant. Ophthalmic Res. 2021;64(4):639–47.
– reference: Mansour SE, Kiernan DF, Roth DB, Eichenbaum D, Holekamp NM, Kaba S, . Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study. Br J Ophthalmol. 2021;105(3):414–9.
– reference: Kane FE, Burdan J, Cutino A, Green KE. Iluvien: a new sustained delivery technology for posterior eye disease. Expert Opin Drug Deliv. 2008;5(9):1039–46.
– reference: Holden SE, Kapik B, Beiderbeck AB, Currie CJ. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials. Curr Med Res Opin. 2019;35(7):1165–76.
– reference: Pessoa B, Castro C, Ferreira A, Leite J, Heitor J, Menéres P, . Changes in ganglion cell layer thickness after treatment with the 0.2 µg/day fluocinolone acetonide implant in vitrectomized and nonvitrectomized eyes with diabetic macular edema. Ophthalmic Res. 2022;65(3):310–20.
– reference: Rübsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):942.
– reference: Campochiaro PA, Nguyen QD, Hafiz G, Bloom S, Brown DM, Busquets M, . Aqueous levels of fluocinolone acetonide after administration of fluocinolone acetonide inserts or fluocinolone acetonide implants. Ophthalmology. 2013;120(3):583–7.
– reference: Gonzalez VH, Campbell J, Holekamp NM, Kiss S, Loewenstein A, Augustin AJ, . Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of protocol I data. Am J Ophthalmol. 2016;172:72–9.
– reference: Merrill PT, Holekamp N, Roth D, Kasper J, Grigorian R; PALADIN Study Group. The 0.19-mg fluocinolone acetonide intravitreal implant reduces treatment burden in diabetic macular edema. Am J Ophthalmol. 2023;248:16–23.
– reference: Mathis T, Papegaey M, Ricard C, Rezkallah A, Matonti F, Sudhalkar A, . Efficacy and safety of intravitreal fluocinolone acetonide implant for chronic diabetic macular edema previously treated in real-life practice: the REALFAc study. Pharmaceutics. 2022;14(4):723.
– reference: Khurana RN, Appa SN, McCannel CA, Elman MJ, Wittenberg SE, Parks DJ, . Dexamethasone implant anterior chamber migration: risk factors, complications, and management strategies. Ophthalmology. 2014;121(1):67–71.
– reference: Brambati M, Borrelli E, Capone L, Querques L, Sacconi R, Battista M, . Changes in macular perfusion after ILUVIEN® intravitreal implant for diabetic macular edema: an OCTA study. Ophthalmol Ther. 2022;11(2):653–60.
– ident: ref10
  doi: 10.2147/OPTH.S206769
– ident: ref17
  doi: 10.3928/23258160-20230215-01
– ident: ref4
  doi: 10.1159/000458539
– ident: ref3
  doi: 10.3390/ijms19040942
– ident: ref5
  doi: 10.1016/j.ophtha.2010.08.016
– ident: ref28
  doi: 10.26355/eurrev_202303_31536
– ident: ref34
  doi: 10.1080/03007995.2018.1560779
– ident: ref24
  doi: 10.3390/pharmaceutics13010072
– ident: ref12
  doi: 10.1016/j.ophtha.2012.09.014
– ident: ref23
  doi: 10.1016/j.ophtha.2012.04.030
– ident: ref21
  doi: 10.1007/s40123-022-00455-5
– ident: ref15
  doi: 10.1097/IAE.0000000000003827
– ident: ref35
  doi: 10.1159/000520411
– ident: ref7
  doi: 10.1155/2018/8289253
– ident: ref8
  doi: 10.1016/j.ajo.2016.09.012
– ident: ref31
  doi: 10.1007/s40123-018-0155-5
– ident: ref40
  doi: 10.1016/j.ophtha.2013.06.033
– ident: ref13
  doi: 10.1097/IAE.0000000000000726
– ident: ref20
  doi: 10.1080/03007995.2017.1366662
– ident: ref26
  doi: 10.1038/s41433-021-01921-3
– ident: ref1
  doi: 10.2337/diacare.26.9.2653
– ident: ref2
  doi: 10.3109/08820539909069541
– ident: ref38
  doi: 10.1038/s41433-021-01542-w
– ident: ref16
  doi: 10.1001/jamaophthalmol.2017.6565
– ident: ref19
  doi: 10.1016/j.exer.2016.08.005
– ident: ref36
  doi: 10.1159/000515306
– ident: ref42
  doi: 10.1016/j.ophtha.2010.02.031
– ident: ref39
  doi: 10.1016/S0140-6736(15)00057-4
– ident: ref37
  doi: 10.1136/bjophthalmol-2020-315984
– ident: ref11
  doi: 10.1167/iovs.04-0905
– ident: ref22
  doi: 10.1007/s00417-022-05564-2
– ident: ref32
  doi: 10.1089/jop.2014.0100
– ident: ref18
  doi: 10.1177/1120672120901691
– ident: ref27
  doi: 10.3928/23258160-20200501-09
– ident: ref41
  doi: 10.31487/j.scr.2020.09.05
– ident: ref29
  doi: 10.1016/j.ajo.2022.09.017
– ident: ref6
  doi: 10.1016/j.ophtha.2010.03.045
– ident: ref25
  doi: 10.3390/pharmaceutics14040723
– ident: ref14
  doi: 10.1016/j.ophtha.2022.01.015
– ident: ref30
  doi: 10.1136/bmjophth-2019-000416
– ident: ref33
  doi: 10.1517/17425247.5.9.1039
– ident: ref9
  doi: 10.1016/j.ophtha.2015.03.024
SSID ssj0015990
Score 2.3459094
Snippet Abstract Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide...
Introduction: The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in...
The aim of this study was to evaluate real-life data on the functional and anatomical outcome of intravitreal fluocinolone acetonide (FAc) in patients with...
SourceID proquest
gale
pubmed
crossref
karger
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 600
SubjectTerms Aged
Corticosteroids
Diabetic Retinopathy - complications
Diabetic Retinopathy - diagnosis
Diabetic Retinopathy - drug therapy
Diabetic Retinopathy - physiopathology
Diabetics
Dropsy
Drug Implants
Edema
Female
Fluocinolone
Fluocinolone acetonide
Fluocinolone Acetonide - administration & dosage
Follow-Up Studies
Glucocorticoids - administration & dosage
Humans
Intraocular Pressure - drug effects
Intraocular Pressure - physiology
Intravitreal Injections
Macular Edema - diagnosis
Macular Edema - drug therapy
Macular Edema - etiology
Male
Middle Aged
Patient compliance
Research Article
Retrospective Studies
Tomography, Optical Coherence - methods
Treatment Outcome
Triamcinolone
Vascular endothelial growth factor
Visual Acuity
Title Real-Life Results after the Administration of a Single 0.19 mg Fluocinolone Acetonide (ILUVIEN®) Implant in Patients with Refractory Diabetic Macular Edema
URI https://karger.com/doi/10.1159/000540459
https://www.ncbi.nlm.nih.gov/pubmed/39159620
https://www.proquest.com/docview/3094821872
Volume 67
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3NbhMxELagoKoXxE-hW0I1ICTgsCLx2uv1sUKJWtQUFAjqbeXYYxSRbqsmOfAuPAMPwZMxtjcrgtTretez8ow934zHnxl7zUXZFyh9rouypABFlbkZKJWTrw2bbrqQJlZbnJcnU_HxQl60-Y5wFuZHqH-O1KgdtwA53PcJWgip77J75HBVKN4b53m3XyC1bgkYaVUhhNxyCG19usd2Axu6LsPd3v84oXYpvp9E3440o8cZPWQPWqgIx0m3j9gdbB6z3XG7Gf6E_ZoQyMvP5h5hgsv1YrWEeOM3EKaDbVJcuPJg4Au5qQVCODsIl99htFiTZkJevaH3LRIKnDuEt6dn02-nw_M_v99B4A6moYd5A58TAesSQuaWBPqbeFPPT0g1NXMLYxNrWmHo8NLss-lo-PXDSd5etpDbQpcrUlPfaTvzzqBDybUXjqMduIAYCYJ4VWnvKmWt5X1DoEZw67AwBDCU1YURxVO209D_HjAYOKcq4SUag2ImuDEVxUlyQL6ywtJhxl5tRr--TpwadYxFpK47bWXsTdBLHeYZjZU17XEBEhEYq-pjgi6y4IRPM9bbepPmh91q3k-a7WRtBPT-e_5pMkxN9bXzGXu5sYM69Bhq0Rq8Wi_rgiLiipCR4hl7lgyk62JjYIe3CH3O9jihopTD6bGd1c0aXxCqWc2OYjbgKJr1X06h7eM
linkProvider Karger AG
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdZ3NbtNAEMdHUFDbS8VHAUMKA0KCHiwSe9f2HqsqUQJJQKFBva02-4Gipm7VJAfehWfgIXgyZr2O1SD16q-xdsae3-7O_hfgfcKyNrPcxSLNMuqg5FmsOnkeU671k24i5aqqthhn_Sn7fM7P6_EOvxbmwtc_V9KojbYAJdxPAS0YF_fhQU7Q7SN6FMfNfAEXohZgpL8KEXKtIbR16z7sejV0kfm9vW8lofpX_DCYvps0q4zTewQHNSriSfDtY7hnyyewO6onw5_C7wlBXjycO4sTu1wvVkusdvxGYjrcFsXFK4cKv1OaWlj0awfx8if2FmvyjB9XL-l6bYkC58bix8Fw-mPQHf_9c4xeO5iaHuclfgsCrEv0I7dk0N1UO_X8wlBTM9c4UlVNK3aNvVSHMO11z077cb3ZQqxTka3ITW0j9MwZZY3liXDMJFZ3jCdGQhCXF8KZItdaJ21FUMMSbWyqCDByLVLF0mewU9L7vgDsGJMXzHGrlGUzlihVkMt4h3JlYTNjI3i3aX15HTQ1ZNUX4UI23orgg_eL9N8ZtZVW9XIBMuEVq-QJoQtPE-LTCFpbV9L3obdOHwbPNrY2Blr_Hf866YZT8tq4CN5u4kD6J_patNJerZcypR5xQWSUJxE8DwHSPGITYC_vMPoG9vpno6EcDsZfXsF-QoQUxnNasLO6WdsjIpzV7HUV3P8A_5rv2Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Real-Life+Results+after+the+Administration+of+a+Single+0.19+mg+Fluocinolone+Acetonide+%28ILUVIEN+%C2%AE+%29+Implant+in+Patients+with+Refractory+Diabetic+Macular+Edema&rft.jtitle=Ophthalmic+research&rft.au=Darwisch%2C+Warda&rft.au=della+Volpe-Waizel%2C+Maria&rft.au=Roberts%2C+Philipp+K.&rft.au=Boden%2C+Karl+T.&rft.date=2024-01-01&rft.issn=0030-3747&rft.eissn=1423-0259&rft.volume=67&rft.issue=1&rft.spage=600&rft.epage=610&rft_id=info:doi/10.1159%2F000540459&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000540459
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0030-3747&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0030-3747&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0030-3747&client=summon